benzotriazinone ethylbromide | 908332-15-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并-1,2,3-三嗪类化合物
• 英文名称: benzotriazinone ethylbromide
• 英文别名: 3-(2-bromoethyl)benzo[d][1,2,3]triazine-4(3H)-one；3-(2-bromoethyl)benzo[d][1,2,3]triazin-4(3H)-one；3-(2-bromoethyl)-1,2,3-benzotriazin-4(3H)-one；3-(2-bromoethyl)-1,2,3-benzotriazin-4-one
• CAS: 908332-15-0
• 化学式: C₉H₈BrN₃O
• 分子量: 254.086
• InChiKey: DUMSTGDMFSDIRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  45
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzotriazinone ethylbromide 在 potassium tert-butylate 、 四丁基碘化铵 作用下， 以 四氢呋喃 、 叔丁醇 为溶剂， 反应 7.33h， 生成 tert-butyl 5-biphenyl-4-yl-3-oxo-2-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]pentanoate
  参考文献：
  名称：

  WO2006/90235

  摘要：

  公开号：
• 作为产物：
  描述：

  靛红酸酐 在 盐酸 、 碳酸氢铵 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 丙酮 为溶剂， 反应 11.24h， 生成 benzotriazinone ethylbromide
  参考文献：
  名称：

  Synthesis and nematicidal evaluation of 1,2,3-benzotriazin-4-one derivatives containing piperazine as linker against Meloidogyne incognita

  摘要：

  To explore new skeleton with nematicidal activity, a series of novel 1,2,3-benzotriazin-4-one derivatives containing piperazine as linker were synthesized and varied fragments were also introduced to increase structure diversity of the new skeleton. Their inhibitory activities in vivo were evaluated against Meloidogyne incognita. The newly prepared compounds A6, A8, A21, A28 and A38 exhibited more than 50% inhibition at the concentration of 20 mg/L. Especially compound A6 displayed 71.4% inhibition against Meloidogyne incognita at the concentration of 20 mg/L. The nematicidal activities varied significantly depending on the types and positions of the substituents, which provided guidance for further structure modification. (C) 2019 Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. Published by Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.cclet.2019.02.033

文献信息

• [EN] MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] INHIBITEURS DE MÉTALLOPROTÉINASE MATRICIELLE
  申请人：RANBAXY LAB LTD

  公开号：WO2012038942A1

  公开（公告）日：2012-03-29

  This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation, which leads to restenosis and ischemic heart faliure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by over-expression and over-activation of matrix metalloproteinase using the compounds.

  这项发明还涉及含有本发明化合物的药物组合物，以及治疗哮喘、类风湿关节炎、慢性阻塞性肺病、鼻炎、骨关节炎、银屑病性关节炎、银屑病、肺纤维化、肺部炎症、急性呼吸窘迫综合征、牙周炎、多发性硬化症、牙龈炎、动脉粥样硬化、干眼症、新生内膜增生，导致再狭窄和缺血性心力衰竭、中风、肾脏疾病、肿瘤转移，以及使用这些化合物治疗过度表达和过度活化基质金属蛋白酶的其他炎症性疾病的方法。
• MATRIX METALLOPROTEINASE INHIBITORS
  申请人：RANBAXY LABORATORIES LIMITED

  公开号：US20140148459A1

  公开（公告）日：2014-05-29

  This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, periodontitis, multiple sclerosis, gingivitis, gingivitis, atherosclerosis, dry eye, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and pounds.

  这项发明还涉及含有本发明化合物的药物组合物，以及治疗哮喘、类风湿关节炎、慢性阻塞性肺病、鼻炎、骨关节炎、银屑病性关节炎、牛皮癣、肺纤维化、肺部炎症、急性呼吸窘迫综合征、牙周炎、多发性硬化症、牙龈炎、牙龈炎、动脉粥样硬化、干眼症、新生内膜增生导致再狭窄和缺血性心力衰竭、中风、肾脏疾病、肿瘤转移和磅的方法。
• 一种具有杀线虫活性的含氮杂环化合物及其制法和用途
  申请人：华东理工大学

  公开号：CN108276352B

  公开（公告）日：2022-09-20

  本发明涉及一种具有杀线虫活性的含氮杂环化合物及其制法和用途。具体地，本发明公开了具有式(I)化合物或其光学异构体、顺反异构体或农药学上可接受的盐，及其制备方法。本发明还公开了包含上述化合物的农用组合物及其用途。上述化合物具有优异的杀线虫活性。
• 5-Phenyl-Pentanoic Acid Derivatives as Matrix Metalloproteinase Inhibitors for the Treatment of Asthma and Other Diseases
  申请人：Palle Venkata P.

  公开号：US20080194565A1

  公开（公告）日：2008-08-14

  The present invention relates to C ompounds having the structure of Formula I: wherein n is an integer from 1 to 5; R 1 is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkynyloxy; R 2 is alkenyl, allcynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, NR 4 R 5 , —NHC(═Y)R 4 , —NHC(═Y)NR 5 R x , —NHC(═O)OR 4 , —NHSO 2 R 4 , C(═Y)NR 4 R 5 , C(═O)OR 6 [wherein Y is oxygen or sulphur], OR 5 , —O(C═O)NR 4 R 5 , O-acyl, S(O) m R 4 , —SO 2 N(R 4 ) 2 , cyano, amidino or guanidino [wherein R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl and m is an integer 0-2; R 5 is hydrogen or R 4 ; R x is R 4 or —SO 2 N(R 4 ) 2 and R 6 is hydrogen, alkyl, cycloalkyl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl]; R 3 is hydrogen, fluorine, alkyl, cycloalkylalkyl or aralkyl; A is OH, OR 4 , —OC(═O)NR 4 R 5 , O-acyl, NH 2 , NR 4 R 5 , —NHC(═Y)R 4 , —NHC(═Y)NR 5 R x , —NHC(═O)OR 4 , —NHSO 2 R 4 , and to processes for the synthesis of the same. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by over-expression and over-activation of an matrix metalloproteinase, using the compounds.

  本发明涉及具有以下结构的化合物：其中n是1到5之间的整数；R1是可选择地取代的烷基、烯基、炔基、环烷基、芳基、杂环烷基、杂芳基、芳基烷基、烷氧基、芳氧基、烯基氧基或炔基氧基；R2是烯基、炔基、芳基、杂环烷基、杂芳基、环烷基、NR4R5、—NHC(═Y)R4、—NHC(═Y)NR5Rx、—NHC(═O)OR4、—NHSO2R4、C(═Y)NR4R5、C(═O)OR6[其中Y是氧或硫]、OR5、—O(C═O)NR4R5、O-酰基、S(O)mR4、—SO2N(R4)2、氰基、胺基亚胺基或胍基[其中R4是烷基、烯基、炔基、环烷基、芳基、杂环烷基、杂芳基、芳基烷基、杂芳基烷基、杂环烷基烷基或环烷基烷基，m是0-2的整数；R5是氢或R4；Rx是R4或—SO2N(R4)2，R6是氢、烷基、环烷基、芳基烷基、杂芳基烷基、杂环烷基烷基或环烷基烷基]；R3是氢、氟、烷基、环烷基烷基或芳基烷基；A是OH、OR4、—OC(═O)NR4R5、O-酰基、NH2、NR4R5、—NHC(═Y)R4、—NHC(═Y)NR5Rx、—NHC(═O)OR4、—NHSO2R4等，以及其合成方法。本发明还涉及含有本发明化合物的药理学组合物，以及治疗哮喘、类风湿关节炎、慢性阻塞性肺病、鼻炎、骨关节炎、银屑病性关节炎、牛皮癣、肺纤维化、肺部炎症、急性呼吸窘迫综合征、牙周炎、多发性硬化症、牙龈炎、动脉粥样硬化、新生内膜增生导致再狭窄和缺血性心力衰竭、中风、肾脏疾病、肿瘤转移和其他炎症性疾病的方法，这些疾病特征是矩阵金属蛋白酶的过度表达和过度激活，使用这些化合物。
• 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
  申请人：Palle Venkata P.

  公开号：US08710261B2

  公开（公告）日：2014-04-29

  The present invention relates to Compounds having the structure of Formula I: wherein n is an integer from 1 to 5; R1 is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkynyloxy; R2 is alkenyl, allcynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, NR4R5, —NHC(═Y)R4, —NHC(═Y)NR5Rχ, —NHC(═O)OR4, —NHSO2R4, C(═Y)NR4R5, C(═O)OR6 [wherein Y is oxygen or sulphur], OR5, —O(C═O)NR4R5, O-acyl, S(O)mR4, —SO2N(R4)2, cyano, amidino or guanidino [wherein R4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl and m is an integer 0-2; R5 is hydrogen or R4; Rx is R4 or —SO2N(R4)2 and R6 is hydrogen, alkyl, cycloalkyl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl]; R3 is hydrogen, fluorine, alkyl, cycloalkylalkyl or aralkyl; A is OH, OR4, —OC(═O)NR4R5, O-acyl, NH2, NR4R5, —NHC(═Y)R4, —NHC(═Y)NR5Rx, —NHC(═O)OR4, —NHSO2R4, and to processes for the synthesis of the same. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by over-expression and over-activation of an matrix metalloproteinase, using the compounds.

  本发明涉及具有以下结构的化合物I：其中n为1至5的整数；R1为可选取代的烷基、烯基、炔基、环烷基、芳基、杂环烷基、杂环芳基、芳基烷基、烷氧基、芳氧基、烯氧基或炔氧基；R2为烯基、炔基、芳基、杂环烷基、杂环芳基、环烷基、NR4R5、—NHC(═Y)R4、—NHC(═Y)NR5Rχ、—NHC(═O)OR4、—NHSO2R4、C(═Y)NR4R5、C(═O)OR6[其中Y为氧或硫]、OR5、—O(C═O)NR4R5、O-酰基、S(O)mR4、—SO2N(R4)2、氰基、酰胺基或脲基[其中R4为烷基、烯基、炔基、环烷基、芳基、杂环烷基、杂环芳基、芳基烷基、杂环芳基烷基、杂环烷基烷基或环烷基烷基，m为0-2的整数；R5为氢或R4；Rx为R4或—SO2N(R4)2，R6为氢、烷基、环烷基、芳基烷基、杂环芳基烷基、杂环烷基烷基或环烷基烷基]；R3为氢、氟、烷基、环烷基烷基或芳基烷基；A为OH、OR4、—OC(═O)NR4R5、O-酰基、NH2、NR4R5、—NHC(═Y)R4、—NHC(═Y)NR5Rx、—NHC(═O)OR4、—NHSO2R4等，以及制备该化合物的方法。本发明还涉及包含本发明化合物的药物组合物，以及使用该化合物治疗哮喘、类风湿性关节炎、COPD、鼻炎、骨关节炎、银屑病关节炎、银屑病、肺纤维化、肺炎症、急性呼吸窘迫综合征、牙周炎、多发性硬化症、牙龈炎、动脉粥样硬化、新内膜增生导致再狭窄和缺血性心力衰竭、中风、肾脏疾病、肿瘤转移以及其他过度表达和过度激活基质金属蛋白酶的炎症性疾病的方法。